CA2493341A1 - Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies - Google Patents

Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies Download PDF

Info

Publication number
CA2493341A1
CA2493341A1 CA002493341A CA2493341A CA2493341A1 CA 2493341 A1 CA2493341 A1 CA 2493341A1 CA 002493341 A CA002493341 A CA 002493341A CA 2493341 A CA2493341 A CA 2493341A CA 2493341 A1 CA2493341 A1 CA 2493341A1
Authority
CA
Canada
Prior art keywords
copper
tetrathiomolybdate
animal
compound
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002493341A
Other languages
English (en)
French (fr)
Inventor
George J. Brewer
Sofia D. Merajver
Dimitri Coucouvanis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2493341A1 publication Critical patent/CA2493341A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA002493341A 2002-07-23 2003-07-23 Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies Abandoned CA2493341A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39780402P 2002-07-23 2002-07-23
US60/397,804 2002-07-23
PCT/US2003/022914 WO2004009072A2 (en) 2002-07-23 2003-07-23 Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies

Publications (1)

Publication Number Publication Date
CA2493341A1 true CA2493341A1 (en) 2004-01-29

Family

ID=30771119

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002493341A Abandoned CA2493341A1 (en) 2002-07-23 2003-07-23 Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies

Country Status (16)

Country Link
US (1) US7888389B2 (enExample)
EP (1) EP1539131A4 (enExample)
JP (1) JP2005538093A (enExample)
KR (1) KR20050025976A (enExample)
CN (1) CN1688303A (enExample)
AU (1) AU2003261222B2 (enExample)
BR (1) BR0312845A (enExample)
CA (1) CA2493341A1 (enExample)
EA (1) EA008683B1 (enExample)
GE (1) GEP20074270B (enExample)
IL (1) IL166385A0 (enExample)
MX (1) MXPA05000875A (enExample)
NO (1) NO20050902L (enExample)
NZ (1) NZ537896A (enExample)
WO (1) WO2004009072A2 (enExample)
ZA (1) ZA200501162B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116528920A (zh) * 2020-10-07 2023-08-01 Cti血管公司 可生物活化的装置和相关方法

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703050B1 (en) 1998-09-04 2004-03-09 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
WO2000018392A1 (en) * 1998-09-25 2000-04-06 Glycox Corporation Limited Fructosamine oxidase: antagonists and inhibitors
EP1487431B1 (en) * 2002-03-08 2012-05-02 PhilERA New Zealand Limited Preventing and/or treating cardiovascular disease and/or associated heart failure
US20070292533A1 (en) * 2002-05-24 2007-12-20 Regents Of The University Of Michigan Copper lowering treatment of autoimmune diseases
US20070248689A1 (en) * 2002-05-24 2007-10-25 Regents Of The University Of Michigan Copper lowering treatment of inflammatory and fibrotic diseases
US7189865B2 (en) * 2002-07-23 2007-03-13 Attenuon, Llc Thiomolybdate analogues and uses thereof
MXPA05000875A (es) 2002-07-23 2005-09-30 Univ Michigan Tetratiomolibdato de tetrapropilamonio y compuestos relacionados para terapias anti-angiogenicas.
US20060100278A1 (en) 2002-08-20 2006-05-11 Cooper Garth J S Dosage forms and related therapies
RU2002128364A (ru) * 2002-10-23 2004-04-27 Институт нефтехимического синтеза РАН им. А.В. Топчиева Способ получения присадки к смазочным материалам (варианты)
EP1633310A4 (en) * 2003-05-27 2006-10-18 Attenuon Llc THIOWOLFRAM ANALOGUE AND ITS USES
EP1729784A1 (en) * 2004-02-23 2006-12-13 Attenuon, LLC Formulations of thiomolybdate or thiotungstate compounds and uses thereof
WO2005083107A2 (en) * 2004-02-24 2005-09-09 Attenuon Llp Inhibition of superoxide dismutase by tetrathiomolybdate: identification of new anti-angiogenic and antitumor agents
WO2006027705A2 (en) 2004-07-19 2006-03-16 Protemix Corporation Limited Synthesis of triethylenetetramines
US20060134708A1 (en) * 2004-10-14 2006-06-22 Northwestern University Detection and treatment of renal cancer
EP2117315A1 (en) * 2007-02-21 2009-11-18 SSV Therapeutics, Inc. Adamantanamines and neramexane salts of thiomolybdic and thiotungstic acids
WO2009009622A2 (en) * 2007-07-09 2009-01-15 Pipex Pharmaceuticals, Inc. Pharmaceutical compositions, including attm, and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases
US20100312139A1 (en) * 2009-06-04 2010-12-09 Board Of Regents Of The University Of Texas System Method for Identifying Mammals at Risk for Elevated intracranial Pressure
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
US20160220500A1 (en) * 2014-11-14 2016-08-04 Kent State University Targeting Intracellular Copper Ions for Inhibiting Angiogenesis Using Nanoparticles of Ternary Inorganic Metal Sulfide M1M2S4 (M1, independently, is Mg, Ca, Mn, Fe, or Zn; M2 = Mo or W) Compounds to Treat Metastatic Cancer
US10874624B2 (en) 2015-02-03 2020-12-29 Kadmon Pharmaceuticals, Llc Stable trientine formulations
AU2018379255B2 (en) * 2017-12-04 2024-10-17 Alexion Pharma International Operations Unlimited Company Bis-choline tetrathiomolybdate for treating Wilson Disease
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909541A (en) 1955-01-07 1959-10-20 Inst Francais Du Petrole Nitrogenous thiomolybdates
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4343746A (en) 1980-12-10 1982-08-10 Gulf Research & Development Company Quaternary ammonium thiomolybdates
US4762705A (en) 1981-11-10 1988-08-09 Adolf W. Schwimmer Cancer therapy with interferon
US4952607A (en) 1982-05-27 1990-08-28 International Copper Research Association, Inc. Copper complex for treating cancer
US4430443A (en) 1982-07-20 1984-02-07 Exxon Research And Engineering Co. Supported carbon-containing molybdenum and tungsten sulfide catalysts, their preparation and use
US4766226A (en) 1984-02-01 1988-08-23 Smithkline Beckman Corporation Antitumor pharmaceutical compositions and methods for treating tumors employing α,ω-bis(disubstitutedphosphino)hydrocarbon derivatives or [α, ω-bis(disubstitutedphosphino)hydrocarbon] di
WO1986003677A1 (en) 1984-12-18 1986-07-03 David Rubin Anti-tumor compositions containing the reaction product of a cytotoxic aldehyde with penicillamine and method of use thereof
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4604278A (en) * 1985-05-17 1986-08-05 Gte Products Corporation Production of ammonium tetrathiomolybdate
US4678667A (en) 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5162231A (en) 1989-10-25 1992-11-10 Cole Dean A Method of using 5,10,15,20-tetrakis(carboxyphenyl)porphine for detecting cancers of the lung
US5057302A (en) 1987-02-13 1991-10-15 Abbott Laboratories Bifunctional chelating agents
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5385933A (en) 1989-02-27 1995-01-31 The United States Of America As Represented By The Department Of Health And Human Services Method for the treatment of cancer by use of the copper complex of S-(methylthio)-DL-homocysteine or the L-enantiomorph thereof
US5100885A (en) 1989-08-01 1992-03-31 Johnson Matthey, Inc. Copper radiosensitizers
US5443816A (en) 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
MX172248B (es) 1989-12-20 1993-12-09 Univ Mexico Procedimiento para la obtencion de nuevos complejos aminoacidatos de cobre mixtos a base de fenantrolinas feniladas como agentes anticancerigenos
US5972922A (en) 1990-06-11 1999-10-26 Alcon Laboratories, Inc. Steroids which inhibit angiogenesis
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
CA2138538A1 (en) 1992-06-19 1994-01-06 Dimitris Skalkos Production and use of imines of porphyrins
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5565491A (en) 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5563132A (en) 1994-06-21 1996-10-08 Bodaness; Richard S. Two-step cancer treatment method
US5583153A (en) 1994-10-06 1996-12-10 Regents Of The University Of California Use of taxol in the treatment of rheumatoid arthritis
US5527533A (en) 1994-10-27 1996-06-18 Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
ATE186222T1 (de) 1995-03-14 1999-11-15 Siemens Ag Ultraschallzerstäuber mit abnehmbarer präzisionsdosiereinheit
ES2177771T3 (es) 1995-03-14 2002-12-16 Siemens Ag Dispositivo atomizador ultrasonico con unidad desmontable de dosificacion de precision.
US5639757A (en) 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
US5954047A (en) 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
IL141550A0 (en) 1998-09-04 2002-03-10 Univ Michigan Methods and compositions for the prevention or treatment of cancer
US6703050B1 (en) 1998-09-04 2004-03-09 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
SI1107795T1 (en) 1998-09-04 2003-06-30 The Regents Of The University Of Michigan Thiomolybdate associated with at least one carbohydrate, and its use for preventing or treating diseases characterized by aberrant vascularization, such as cancer, wet type macular degeneration, rheumatoid arthritis
JP2005504060A (ja) * 2001-08-24 2005-02-10 メイン・メデイカル・センター・リサーチ・インステイテユート 銅依存性の非伝統的前炎症性サイトカイン輸送およびそれに関連する方法、組成物およびキット
US6855340B2 (en) 2002-05-24 2005-02-15 Regents Of The University Of Michigan Copper lowering treatment of inflammatory and fibrotic diseases
MXPA05000875A (es) 2002-07-23 2005-09-30 Univ Michigan Tetratiomolibdato de tetrapropilamonio y compuestos relacionados para terapias anti-angiogenicas.
US7189865B2 (en) * 2002-07-23 2007-03-13 Attenuon, Llc Thiomolybdate analogues and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116528920A (zh) * 2020-10-07 2023-08-01 Cti血管公司 可生物活化的装置和相关方法

Also Published As

Publication number Publication date
US20040259945A1 (en) 2004-12-23
EA008683B1 (ru) 2007-06-29
EP1539131A2 (en) 2005-06-15
BR0312845A (pt) 2005-06-07
EA200500244A1 (ru) 2005-12-29
IL166385A0 (en) 2006-01-16
KR20050025976A (ko) 2005-03-14
CN1688303A (zh) 2005-10-26
GEP20074270B (en) 2007-12-25
JP2005538093A (ja) 2005-12-15
NZ537896A (en) 2007-12-21
EP1539131A4 (en) 2009-07-08
MXPA05000875A (es) 2005-09-30
AU2003261222B2 (en) 2009-07-09
US7888389B2 (en) 2011-02-15
WO2004009072A3 (en) 2004-04-08
ZA200501162B (en) 2005-09-05
WO2004009072B1 (en) 2004-07-08
NO20050902L (no) 2005-04-19
WO2004009072A2 (en) 2004-01-29
AU2003261222A1 (en) 2004-02-09

Similar Documents

Publication Publication Date Title
AU2003261222B2 (en) Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
US6703050B1 (en) Methods and compositions for the prevention or treatment of cancer
EP1107795B1 (en) Thiomolybdate associated with at least one carbohydrate, and its use for preventing or treating diseases characterized by aberrant vascularization, such as cancer, wet type macular degeneration, rheumatoid arthritis
CZ289629B6 (cs) 2,4-Disulfonyl-alfa-fenyl-terc.butylnitron, jeho soli, farmaceutická kompozice s jeho obsahem a pouľití
KR20230170797A (ko) 이식편 대 숙주 질환의 치료 및 예방 방법
KR19990036138A (ko) 암 성장을 억제하기 위한 플루코나졸의 용도
AU2021240762A1 (en) Cyclophilin inhibitors and uses thereof
EP1234585A2 (en) Methods and compositions for the prevention or treatment of cancer
KR20220124739A (ko) 암의 치료를 위한 병용 요법
ZA200101334B (en) Methods and compositions for the prevention or treatment of cancer.
US20080213396A1 (en) Copper Lowering Treatment Of Cardiac Disease
CN115212192B (zh) 二苯甲酮衍生物在制备抗肾脏纤维化药物中的应用
EP4570247A1 (en) Combined agents with synergistic effect against gliomas
JP2025040508A (ja) 代謝性骨疾患治療剤およびそれを含む医薬組成物
JP2025521628A (ja) カルシニューリン阻害剤の間欠的投与のための組成物
WO2022098808A1 (en) Therapeutic agents for treating hepatocellular carcinoma
JP2022551373A (ja) 三環式誘導体を用いた脳卒中の治療方法
JP2022053450A (ja) 唾液腺癌の治療
WO2009047291A2 (en) Use of quaternary pyridinium salts for inhibiting cancer metastases
JP2007008834A (ja) 糖尿病合併症治療薬

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued